224 related articles for article (PubMed ID: 31781962)
1. Biodistribution and post-therapy dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
EJNMMI Res; 2019 Nov; 9(1):102. PubMed ID: 31781962
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
3. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Safety and Dosimetry of
Fernández R; Eppard E; Lehnert W; Jiménez-Franco LD; Soza-Ried C; Ceballos M; Ribbeck J; Kluge A; Rösch F; Meckel M; Zhernosekov K; Kramer V; Amaral H
J Nucl Med; 2021 Aug; 62(8):1126-1132. PubMed ID: 33419945
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
6. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and dosimetry of
Li H; Pei W; Yang X; Qu G; Hua Q; Liu L; Wang Y; Xu T; Chen Y
EJNMMI Res; 2024 Mar; 14(1):30. PubMed ID: 38517637
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Kamaldeep ; Thapa P; Wanage G; Tervankar S; Kaisar S; Ranade R; Basu S; Das T; Banerjee S
Nucl Med Commun; 2021 Oct; 42(10):1076-1084. PubMed ID: 34528928
[TBL] [Abstract][Full Text] [Related]
9. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
10. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
11. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and Internal Dosimetry of 68 Ga-DOTA-IBA PET Imaging for Patients With Bone Metastases.
Yang J; Deng J; Fan D; Chen G; Lu Z; Liu H; Mok GSP; Chen Y
Clin Nucl Med; 2023 Oct; 48(10):847-852. PubMed ID: 37418288
[TBL] [Abstract][Full Text] [Related]
14. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
[TBL] [Abstract][Full Text] [Related]
15.
Zhang J; Lin Z; Zhang X; Lin R; Cui M; Miao W; Yao S
Front Bioeng Biotechnol; 2021; 9():811972. PubMed ID: 35155411
[No Abstract] [Full Text] [Related]
16. [
Yadav MP; Ballal S; Meckel M; Roesch F; Bal C
EJNMMI Res; 2020 Oct; 10(1):130. PubMed ID: 33113035
[TBL] [Abstract][Full Text] [Related]
17. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
18. Preclinical dosimetric studies of
Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases : A Phase 0/I Study.
Qiu L; Wang Y; Liu H; Wang Q; Chen L; Liu L; Wang L; Feng Y; Chen Y
Clin Nucl Med; 2023 Jun; 48(6):489-496. PubMed ID: 36976706
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution, dosimetry, and temporal signal-to-noise ratio analyses of normal and cancer uptake of [
Doot RK; Young AJ; Daube-Witherspoon ME; Alexoff D; Labban KJ; Lee H; Wu Z; Zha Z; Choi SR; Ploessl KH; Schubert EK; Lee H; Zhu L; Reddin JS; Karp JS; Kung H; Pryma DA
Nucl Med Biol; 2020; 86-87():1-8. PubMed ID: 32361089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
